Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Entegris Inc (ENTG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Entegris Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Entegris Inc trades at $138.44 (market cap $20.57B). The key difference: Entegris Inc is far larger — about 4.6× ACADIA Pharmaceuticals Inc.'s market cap, and Entegris Inc pays a 0.3% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ENTG | |
|---|---|---|
Market Cap | $4.49B | $20.57B |
Sector | Health | Technology |
52-Week High | $28.06 | $184.00 |
52-Week Low | $20.06 | $68.80 |
Enterprise Value | $3.69B | $23.89B |
Dividend Yield | — | 0.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ENTG is trading at $135.08, down 7.9% today, with a bearish technical signal and neutral oscillators. The company reported strong Q1 2026 earnings of $0.86 per share, beating estimates, and maintains solid fundamentals with $3.2B revenue and 8.18% net income margin. Recent developments include a strategic cross-licensing agreement for EUV lithography and appointment of a new CFO.
Wall Street maintains a bullish outlook with 65% buy ratings and $178.40 consensus price target, representing 32% upside potential. Key risks include premium valuation (P/E 83.91), semiconductor cycle sensitivity, and execution challenges. The stock offers growth exposure to AI-driven semiconductor demand but requires careful monitoring of quarterly execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
